Clinical Trials Logo
  1. Home
  2. Schizoaffective Disorder
  3. NCT00683709

Specialized Clozapine Clinic for Bipolar and Schizoaffective Disorder

Schizoaffective Disorder Clinical Trial

Official title:
Metabolic Side Effects, Diet and Exercise Counseling and Brain Function in a Naturalistic Clinical Trial of Clozapine for Treatment Resistant Bipolar and Schizoaffective Disorder

Clinical Trial Summary

Bipolar Disorder (BD) and Schizoaffective Disorder (SA) clients.

- determine if after 12 months of treatment with clozapine, the BMI changes with clients who are councelled as usual regarding weight gain while on Clozapine.

- determine if after 12 months of treatment with clozapine, the BMI changes with intense, structured councelling about diet and exercise.

Clinical Trial Description

To determine whether the changes in BMI produced in subjects with Bipolar Disorder (BD) and Schizoaffective Disorder (SA) by 12 months of treatment with clozapine, can be diminished after an intense and highly structured intervention focused on diet and exercise, compared with the usual brief counseling regarding weight gain on this drug. ;

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00683709
Study type Observational
Source St. Joseph's Healthcare Hamilton
Contact
Status Completed
Phase Phase 4
Start date January 2007
Completion date July 2011
View Details
See also
  Status Clinical Trial Phase
Completed NCT00212784 - Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935) Phase 3
Completed NCT04284813 - Families With Substance Use and Psychosis: A Pilot Study N/A
Completed NCT01878513 - Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis N/A
Recruiting NCT05030272 - Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings N/A
Recruiting NCT04298450 - ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention N/A
Not yet recruiting NCT04551027 - Assessing the Effect of Compensatory Cognitive Intervention Among People With Severe Mental Illness N/A
Terminated NCT02796144 - MEtformin and Lorcaserin for WeighT Loss in Schizophrenia Phase 4
Completed NCT02901587 - Study Investigating the Effect of Lu AF35700 on Cardiac Repolarization in Men and Women With Schizophrenia and Schizoaffective Disorder Phase 1
Completed NCT02160249 - RISE (Rehabilitation Intervention for People With Schizophrenia in Ethiopia) N/A
Recruiting NCT02986490 - Magnesium Variations and Cardiometabolic Risk in Patients With Antipsychotic Drugs N/A
Completed NCT02091388 - Bioavailability of LY03004 and Risperdal® Consta® Phase 1
Terminated NCT02234752 - Galantamine and Memantine Combination for Cognitive Impairments in Schizophrenia Phase 2
Completed NCT02417142 - Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia Phase 4
Completed NCT01975584 - Neuroendocrine and Immune Response to Stress in Schizophrenia N/A
Terminated NCT02149823 - Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations Phase 1
Completed NCT01992393 - Targeted Self-Management for Epilepsy and Serious Mental Illness (TIME) N/A
Completed NCT01945333 - Personalized and Scalable Cognitive Remediation Approaches N/A
Completed NCT01683539 - Understanding How Cognitive Remediation Works N/A
Completed NCT01658150 - Evaluating Isradipine for Cognitive Enhancement in Schizophrenia and Schizoaffective Disorder N/A
Completed NCT01193153 - A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder Phase 3